Funding first, then licensing

Aptamer Group (LSE:APTA), the AIM-quoted developer of synthetic binders for life sciences, entered its new financial year with more cash than it had for some time and a growing set of licensing arrangements. This article looks at how the company extended its expected cash runway to 2028, what its latest trading update reported, and how far licensing income has progressed.

What Aptamer does

Aptamer develops Optimer binders, synthetic molecules that the company describes as next-generation alternatives to antibodies. They can be used in diagnostics, laboratory tools and therapeutic programmes. The group earns fees from development projects with partners and is seeking to turn successful projects into licences and royalties. Its programmes include work with Metir plc on Cryptosporidium, a collaboration with Unilever targeting a bacterial enzyme, a delivery programme with Invizius, a radiopharmaceutical programme with a top-three pharmaceutical company, and a rapid test for fortified foods with Imperial College London. On 8 July 2026 it also announced the start of an Ebola diagnostic test programme. Dr Arron Tolley is chief executive.

How the runway was extended

On 26 March 2026, Aptamer announced it had raised £4.275m gross through the issue of 712,500,000 new shares at 0.6p each, through a placing and subscription. Investors received one Warrant for every three shares, exercisable at 0.9p within two years. A separate, smaller retail offer of up to £0.5m was also launched. The company said most of the proceeds would go towards developing an AI model for RNA-binding proteins and transcription factors and generating in-vivo animal data for its radiopharmaceutical programme, with a smaller portion for working capital. Directors participated in the placing. The chief executive said the fundraise would "materially extend our runway to 2028". Before the raise, the company had reported cash of £1.5m at 31 December 2025, with runway then extending only to the second quarter of 2027.

The trading update

On 13 July 2026, Aptamer reported unaudited Revenue of £1.5m for the year to 30 June 2026, up 25% from £1.2m. It said net proceeds of £4.1m from the April fundraise extend its runway to at least 2028. The order book for FY2027 stood at £0.6m, and the broader sales pipeline had grown 55% to £4.8m from £3.1m in January 2026.

On licensing, the company reported initial revenues from agreements signed in December 2025 with Twist Bioscience and Alphazyme LLC, and positive evaluation results from global hot-start enzyme suppliers. It also said an Optimer product had been delivered to a global life sciences company for customer validation under a 2% Royalty arrangement on diagnostic kits. Dr Tolley said: "we believe the Group is well positioned to continue its progress into FY2027 and beyond". On 20 August 2026, the company announced the appointment of a joint corporate broker.

Risks to consider

Aptamer remains a small business, with annual revenue of only £1.5m, and the trading update did not disclose profit or EBITDA figures. Licensing income is at an early stage, and royalty arrangements only produce meaningful revenue if partners' products sell. Pipeline value does not ensure orders, and the conversion of evaluation work into commercial contracts can take many months in diagnostics and pharmaceutical markets. The large share issue in March diluted existing holders, and the outstanding warrants could add further shares if exercised. Audited final results for FY2026 will provide a fuller view of costs, losses and cash.

Conclusion

Aptamer extended its cash runway to 2028 by raising £4.275m gross in March 2026 at 0.6p per share, and it reports growing revenue and an expanding pipeline. Licensing income has started, through deals with Twist Bioscience and Alphazyme, but it is not yet large enough to show that the model can sustain the Business without further funding.